Skip to content
Status Epilepticus & the EcLiPSE Trial episode artwork

Jul 26, 2019 17 min

Status Epilepticus & the EcLiPSE Trial

from Take Aurally Hosted by Take Aurally

Status epilepticus is the most common paediatric neurological emergency in the UK and the second most common reason for unplanned PICU admission in the UK. Dr Colin Gilhooley defines status epilepticus before discussing the EcLiPSE trial: Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial This was a UK wide trial across 30 Emergency Departments (including our own in Nottingham) comparing Phenytoin as the standard 2nd line treatment to Levetiracetam as an alternative with a smaller side effect profile. The result was (spoilers): NO SIGNIFICANT DIFFERENCE. Colin take us through the potential consequences of this, how this might change practice as well as what it was like to be involved in the trial and what deferred consent might mean in the future. You can find the blog for this episode at https://www.takeaurally.com/paediatric-emergency-medicine/2019/7/3/paediatric-status-epilepticus-amp-the-eclipse-trial As ever you can subscribe to Take Aurally through Apple Podcasts and Soundcloud AND we're also on Spotify: open.spotify.com/user/hk2tt55xd97pcz4xoj43nydyy Remember to follow us and NUH DREEAM on Facebook and Twitter We're now also on Instagram where you can find our whole collection of Take Visually infographics: www.instagram.com/takeaurally/

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Status Epilepticus & the EcLiPSE Trial

0:00 17:59
of matches

Transcript Auto-generated, may contain errors

Hello, welcome back to Take Orally and this episode is on paediatric status epilepticus and in particular a rather interesting trial that was published earlier this year, the Eclipse trial. To take us through that we have paediatric A&E consultant Colin Gilholy. Hello Colin. Hi there, pleasure to be here. Thank you for coming. As ever, all information is correct at the time we are recording this. Any and all guidelines mentioned are correct for Nottingham University Hospitals NHS Trust and any views expressed are Colin's or mine.

So, Colin, we should probably do another podcast at another point, focusing just on sieges in kids, because there's febrile convulsions, etc. But this one we're going to be looking solely at status epilepticus, and then, as we said, this Eclipse trial, which here at the QMC we were involved in, and I know has received a lot of interest internationally, and it's been all across social media. Shall we start by just really defining status epilepticus, and talking about status epilepticus in kids particularly? Yeah. I was a bit of a geek at med schools, you can probably guess. Status epilepticus was one of those fun phrases I quite liked learning, you know, it sounds quite cool to say. But what is status epilepticus? So status epilepticus is the most common paediatric neurological emergency worldwide, and it's defined as a prolonged seizure lasting greater than five minutes. Okay. You'll notice that we've had an algorithm for status epilepticus in paediatric arms, but the paediatric status protocol really hasn't changed for quite a long time now.

And as such, this was an exciting trial in that it wanted to look at how we change the drugs which we use specifically. Other points of interest within this trial are that it was a very large, open, multi-centred, randomised trial. There was a similar trial with a similar recruitment strategy done in Australia at the same time, called the CONCEPT trial, and actually was published in The Lancet alongside this journal. And it was a deferred consent trial, so one of the first large trials in the UK in children, in which they were randomised, the treatment was given, and then consent was sought from the parents afterwards. So there was quite a few interesting points in this trial. Sure, cool. And I've been practising how to say this drug, Levatiracetam. Levatiracetam. Best is to call it Keppra. Other brands are available, I'm sure. So, yeah, so, state septic, as you said, most common, and the second most common reason for an unplanned PICU admission in the UK.

Mortality low, but due to hypoxia and brain injury, there is a lot of morbidity attached to it. Absolutely. And the link is that the longer you are seizing, the greater your risk of damage afterwards. So obviously you want to terminate this seizure as soon as possible. And alongside that, the longer a seizure lasts, the harder it is to terminate. Ah, I did not do that. So they go alongside each other, so more risk of damage and harder to stop. Cool. And usually...

The first time treatment I'm writing thinking is a couple of doses of benzodiazepines, or whatever that child, if they are known to have seizures, they usually have a rescue remedy, don't they? Yeah, so some children may not have responded to the standard status protocol, and they might have had specific agents put in place for them, but the standard national guideline is benzodiazepine, wait 10 minutes, give a second benzodiazepine, wait 10 minutes, and then consider phenytoin. That was the current guideline. Yeah, so then phenytoin was our second line, and then if that didn't work, it's RSI, too, or if you go to sleep. Yeah, and there's some stuff written in there about considering ferroaldehyde.

So this is the Eclipse trial we are talking about, which I'm not sure if we've called its name yet. And the official title is from the Lancet in earlier this year, from April 17th, Levitiracetum versus phenytoin for second-line treatment of pediatric convulsive status epilepticus, brackets, Eclipse, colon, a multicenter, open-label, randomized trial. Cool. And this involved 1,432 patients were assessed, with 152 allocated to Levitiracetum, 134 to phenytoin. So lots of people. It was a big multi-center trial. Lots of big multi-center trial. And what did they find? They found that neither drug was superior. Smashing. Which might not seem like very much. It might seem disappointing. But actually, there was no statistically significant differences in cessation of seizures with either particular drug. So Kepra is no better but no worse than phenytoin? Correct. Therefore, the inverse is also true. Phenytoin is no worse but no better than Kepra. Cool.

And so from that point of view, you can then debate whether you think that that means we should change the drug or not. That's an interesting conversation. So phenytoin is an old drug. It has side effects, especially in terms of cardiac arrhythmias. And so the question is, is Kepra potentially a safer drug? And as such, if it's as effective, or there's no statistically significant difference between the two, should we therefore...

move to that drug? Or should it be included and make it a clinician's choice? And all of those things are currently up for debate. This trial has obviously come out quite recently, and so it will take a time for this to filter through and lead itself into how it changes guidelines in clinical practice. And was this reflected in the concept trial as well? Absolutely, they find it exactly the same. And I think what we'll find is that as those two trials, from a methodology point of view, are reasonably similar, that we might find a meta-analysis coming out of that in the future to help

help us understand more in an even bigger trial about whether there was definitely no statistically significant difference. Cool. And so you mentioned sort of side effect profile. So what are the downsides of phenytoin then? You said this was the old treatment. What are the downsides there? So I think in terms of it's known to cause cardiac arrhythmias and there have been in the past cases where phenytoin has been responsible for the death.

always been implicated in the death of children, presenting with status epilepticus. So from that point of view, it is a drug which is potentially not as clean, for want of a better word, as potentially Keppra. The flip side of that is Keppra leviterocetal is a newer drug, so maybe we just haven't used it for as long. And so maybe we need to understand how it works in children a bit better before we start to make those changes. the move was made I think a year ago, phenytoin was no longer the second line, it was Keppra became the first-choice second-line drug. And sodium valparate was also being considered as well, unless you were a female of child-bearing age who had liver disease, in which case phenytoin then comes back into it. So primarily part of that was the fact that if you're on phenytoin, you need cardiac monitoring, so therefore it's a bed issue as well that matters as well as you set the side effect profile.

Were you involved in any cases of this? So I recruited to this trial. Marvelous, do you want to tell us a bit about that? Yeah, so as I say, from a recruitment point of view, it's interesting in terms of they were randomised in the emergency department. We had two treatments, both of which we know work, but the question was which one works better. So in terms of that, the child has always been giving an agent which we knew could stop status epilepticus, but without taking consent from a patient or their parents prior to giving the drug.

which was my first experience of that. But something, when the feedback, when it's been discussed with parents, was actually not really a concern from the parents' point of view. The way they saw it was their child was getting a drug which couldn't work. And therefore, we were trying to find out which one works better. And actually, overwaringly, parents were actually very much in support of that. And that's a really good outcome from this trial on its own from that point of view.

Deferred consent in the emergency department is an acceptable way to conduct research and as such gives us a way of looking at more clinical questions like this where there are two agents in place. This is recruiting to a trial of a true emergency in an emergency situation and the trial worked, recruitment was excellent. And so it kind of gives us a platform. going forward for potentially how to conduct further trials, which is very exciting. Excellent. And were you involved in that discussion with any parents? I wasn't. We looked up to our research nurses. You know, Jamie, here, we've got a fabulous team of research nurses working in the emergency department. So they were responsible for the deferred consent. And as I say, the feedback from that is actually hugely positive. And so we've obviously seen that there wasn't much of a difference in terms of the primary outcome. There's a lot of secondary analysis going on with the paper, having a look at things, because there's a lot of information that was collected as part of this.

Some of those questions about what drugs were given pre-hospital, and the time of the seizure starting was collected, the time of their arrival into hospital, the time of the paramedic on site, all of those things are known. So we can see how people gave drugs pre-hospital, we can see how long it took them to give the drugs, get them drawn up and get them into the patient, and see where the delays are in it. So I think there's a whole body of research coming out of this trial with more that will actually influence the status protocol going forward. One of the things about the status protocol in children is that it's different from the Australian one. So the time between the benzodiazepines in Australia is five minutes, and our time is 10 minutes. And so I think what we'll probably see is that even within that 10 minutes, it probably takes longer for them to get into the patient. And so the question with this is that, while this hasn't shown a difference, it's kind of refocused us on status and asked us, well, where do we go next? This is a guideline that hasn't changed for a long time. Is there things we can change now? Do we need to consider the order? Do we consider when we give specific drugs? Do we need to change our pre-hospital drugs? Should it be two doses of benzo? Should we be giving ambulance crews different drugs? Could they have levotiracetam?

in the back of an ambulance, could that be an option to give instead? Are there other agents that we use? So coming out of the Twitter discussions on this paper was, why don't you just give propofol? OK. Give it early, give it quick. We know the two things we talked about earlier was the longer it lasts, the more chances of brain damage. And the harder it is to treat.

So just stop it. Stop it as fast as you can. There's obviously a huge implication to that. But the question is about where do we go from this? And I think this will be a slow look at how we look at the drugs that we give and looking to update this policy. And I think this might well just be the start. We know we've got a trial template almost for deferred consent for how it would work. And it's just about finding out what part of the question we could potentially ask next. Is it going to five minutes between benzos? Is it adding another drug in earlier, like liver tiracetam? Is it the use of actually completely different drugs? So propofol, ketamine, you know, they're all out there. And so hopefully, going forward, there could be some

more questions being raised about this and some more research being done, which is exciting. The thing that sort of strikes me when I look at it, it's the participants, they range from six months to 18, just under 18 years. That's a huge variation in, not just, well, in age, but physiology. Massive differences. I suppose it shows the thing of paediatric research versus adult research, because you could argue that, you know, 18-year difference there, but if you had an 18-year-old versus a 36-year-old, how much is actually different, whereas between a six-month and 18, that's quite a lot of difference. And so that's where you have to say,

be realistic about well that's the treatment that they get currently yeah and there is that massive physiological difference the potential causes of seizures could be massively different and therefore many different agents would be needed but that's not realistic so this is about having something that works in practice And I think a seizure, a status epileptica's guideline for every single, for less than one, one to five, would be incredibly difficult and likely cause patient safety issues in terms of people being put on the wrong wall and not having to remember so much. But yeah, you're right, the physiology is huge. The potential causes are hugely different. But that is paediatric to the nutshell. Well, that's kind of the point I wanted to make there, I think, just to sort of emphasize that. And then I just want to finish wrapping up, really, with thinking, because we've been mentioning this thing about being significantly superior. Yes. And I think this is something that...

gets lost because I think in layman's terms, significant means something completely different to in research terms. So if you say somebody in the street, there is a significant difference. They are expecting night versus day. Whereas in research, you're talking about a 5% chance that this happened by reason, a p-value of 0.05 essentially, which is nothing. So I think that's a point worth emphasizing. Absolutely.

And it's important when you look at especially comparing drug trials about everything in this trial is set up to meet the minimum standards for what it means when you're comparing two drugs. And when you compare them about saying, what difference do I want to see? What difference do I expect to see between two drugs in order to calculate your sample sizes? It obviously gets reasonably complex with the statistics. But I think the good thing to say is this was a very robust trial. And there's some lovely infographics that have already been produced by this. So there's one from Don't Forget the Bubbles, which I'm sure you could share a link to, which kind of highlights the main...

outcomes of the trial. Sweet. And just as yourself, you're a consultant in paediatric emergency medicine, as we know. What do you think will happen? Has it changed your practice? I know we're talking very much it's guideline-driven, so what do the guidelines say we follow in paediatric emergency medicine, but do you think that this will change things? I think it probably will with time. Jamie, I think we'll see slowly as moving towards using levity receita more and more. There's no real difference in terms of cost, so I think we probably will move towards it. But I think in terms of how to diagnose change, that will probably take years. Years.

Fair enough. Cool. Thank you very much, Colin. Thank you very much. And I will put the Lancet link, it's all available, so I'll put that on the blog entry for this podcast at takeorally.com. As ever, you can subscribe to Take Orally at Apple Podcasts, Spotify, SoundCloud. We are on Facebook, Twitter, we're on Instagram. And remember, NUH Dream is also on Facebook and Twitter. Thank you so much, Colin. Thank you very much. Thank you for listening. Bye-bye.

Frequently asked questions

How long is this episode of Take Aurally?

This episode is 17 minutes long.

When was this Take Aurally episode published?

This episode was published on July 26, 2019.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this Take Aurally episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.